FDA adds vision-loss warning to all GLP-1 drugs

The FDA said on Monday November 9 it will add a rare vision-loss warning to every GLP-1 drug. FDA scientists found the eye problem in about 6 of every 100,000 patients who took one for a year. Claude Wallet and David J. Taylor hold Eli Lilly (LLY) long.